Search the hub
Showing results for tags 'Side effects'.
-
News Article
Millions of people with breast cancer could safely avoid chemotherapy as scientists have developed a DNA test that can distinguish between patients who are likely to benefit from the treatment and those who are not, according to trial results. The international study found that more than two-thirds of its participants could be spared the side of effects of chemotherapy and treated with hormone therapy alone. Chemotherapy can cause fatigue, nausea, hair loss, a weakened immune system and fertility issues. The study, led by University College London (UCL), involved more than 4,000 newly diagnosed patients over the age of 40 in the UK, Norway, Sweden, Australia, New Zealand and Thailand. The primary treatment for breast cancer is usually surgery to remove tumours. Chemotherapy is often recommended afterwards to diminish the risk of return. It is also regularly offered to people with early-stage breast cancer that has spread to the nearby lymph nodes. Clinicians are concerned the treatment provides little benefit to those with the most common type of breast cancer, UCL said. The university said more than 5,000 NHS patients a year could avoid chemotherapy as a result of the trial. Read full story Source: BBC News, 30 May 2026- Posted
-
- Cancer
- Womens health
-
(and 3 more)
Tagged with:
-
News Article
Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride. Following an additional detailed review of the evidence, including the outcome of a European regulatory review, the MHRA has published a new Drug Safety Update and is updating product information for medicines containing finasteride and dutasteride to provide clearer guidance for healthcare professionals and patients. Finasteride is used to treat male pattern hair loss at a dose of 1mg, and benign prostatic hyperplasia at a dose of 5mg. Dutasteride (0.5mg) is used to treat benign prostatic hyperplasia. The updates include: strengthened warnings in the product information for finasteride 1mg for androgenetic alopecia to clarify that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported with and without mood alterations. a precautionary warning added to the product information for dutasteride to note that mood alterations have been reported with a medicine in the same class, finasteride. Existing UK patient alert cards for finasteride, introduced in 2024, remain in place. These cards highlight the risks of sexual dysfunction, depression and suicidal thoughts and advise patients on what action to take if side effects occur. Read full story Source: MHRA, 11 May 2026- Posted
-
- Medication
- Adverse reaction
-
(and 1 more)
Tagged with:
-
Content Article
Pelvic mesh complications questionnaire
Patient Safety Learning posted an article in Medical devices (existing)
Sling the Mesh in collaboration with researchers at the RCSI University of Medicine and Health Science are conducting a survey of people with pelvic complications. Participation involves an online survey that will take approximately 30 minutes. You are eligible to participate if you were implanted with any type of pelvic mesh (incontinence, bladder leaks, rectopexy) in a UK facility after 1 January 1998 and have experienced any pelvic mesh related complication. Find out more from the link below.- Posted
-
- Medical device
- Questionnaire
- (and 3 more)
-
News Article
Warnings about common medications that can cause impulsive behaviours, such as sex and gambling addictions, are being officially reviewed after BBC News identified an error in drug leaflets. Side effects of a family of drugs used to treat Parkinson's, Restless Legs Syndrome (RLS) and other conditions have led to huge debts, broken marriages, criminality and suicide, our year-long investigation found. More than 350 affected people have contacted the BBC during that period. One in six Parkinson's patients taking the drugs are affected by impulse control disorders, the clinical term for these behaviours, according to one study cited as the largest of its kind. Yet those side effects are described as "uncommon" in leaflets for one of the drugs, suggesting they only affect fewer than one in a hundred patients. After being alerted by the BBC, the UK's drug safety regulator said that "an error has been identified" and it would be changing that label to "common". In response to our findings, the Medicines and Healthcare products Regulatory Agency (MHRA) has also begun reviewing warnings for all eight of these medications, which are known as dopamine agonist drugs. Boehringer Ingelheim, the developer of Pramipexole - the Parkinson's drug with impulsive behaviours listed as "uncommon" - said the regulator had approved its leaflets and that it was committed to improving patient safety. Neither it nor the MHRA were able to say how long the error had existed for, but the BBC has discovered its inclusion in a leaflet from 2021 - meaning patients have been misled for at least five years. The MP who heads the Health Select Committee has told us she "wants answers" from the MHRA and believes it should apologise to families for the mistake. "I just can't even begin to imagine hearing what they've been through - abuse, financial ruin, all that you've uncovered - and then to find out that they could have been so much better forewarned," said Layla Moran. Read full story Source: BBC News, 28 March 2026- Posted
-
- Medication
- Side effects
-
(and 1 more)
Tagged with:
-
News Article
Health warning as common painkiller linked to kidney damage
Patient Safety Learning posted a news article in News
Consumers are being urged to exercise caution when using common anti-inflammatory medications such as ibuprofen for pain relief due to potential adverse effects on kidney function. Those with a higher risk of kidney disease, including individuals with diabetes or high blood pressure, should be especially careful, warn Kidney Care UK and the National Pharmacy Association (NPA). Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, and diclofenac can elevate blood pressure and damage blood vessels within the kidneys. Olivier Picard, chair of the NPA, said: “Medicines have the power to harm as well as to heal. “Although NSAIDs, such as ibuprofen, are effective and safe medicines, patients should be aware of their impact – particularly if a patient is at increased risk of developing kidney disease – and consider alternative medication where appropriate. “If a patient has concerns about their usage of NSAIDs, they should speak to their pharmacist who can advise them. “Pharmacists are experts in medicines and are best placed to offer advice to people who may be concerned about any potential long-term effect of some medicines and can help patients effectively manage pain.” Read full story Source: The Independent, 13 March 2026- Posted
-
- Medicine - Nephrology
- Pain
-
(and 2 more)
Tagged with:
-
Content Article
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks. Advice for healthcare professionals: Gabapentinoids (pregabalin and gabapentin), benzodiazepines and z-drugs are three classes of medicines used to treat a variety of conditions such as neuropathic pain, anxiety and insomnia. Specialist use of these medications for conditions such as epilepsy, or sedation during medical procedures are not included in this review. All three classes of medications are known to pose risks of addiction, dependency, withdrawal and tolerance. The Summary of Product Characteristics, Patient Information Leaflets and Outer Packaging of these medicines will have strengthened warnings to better communicate the risks of addiction, dependency, withdrawal and tolerance to healthcare professionals and patients. Updates are in progress and will be rolled out over the coming months. Prior to starting treatment with these medicines, a discussion should be held with patients to put in place a strategy for reducing or ending treatment. By doing this the risk of addiction, dependence, and drug withdrawal syndrome is reduced. NICE guideline, NG215, has resources that include visual summaries which are available to support these discussions. The Agency has also developed additional patient resources for benzodiazepines, gabapentinoids and z-drugs which highlight key messages concerning these risks and should be made available to patients when these medications are prescribed. Addiction and dependence are related but have distinct presentations. Healthcare professionals are reminded of the importance of using non-judgmental language when discussing these terms. Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of symptom control as initially experienced. This could be a sign that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to reduce symptoms of withdrawal. Tapering from a high dose may take weeks or months. Patients should be informed of this when the medication is first prescribed and should be encouraged to speak to their healthcare professional or prescriber before stopping their medicine. See NICE guideline NG 215 for identifying and managing withdrawal symptoms. Provide regular support especially to individuals at increased risk of drug withdrawal syndrome, such as those with current or past history of substance use disorder (including alcohol misuse) or mental health disorder. Addiction, dependence, withdrawal or tolerance in response to these medications can be reported via the Yellow Card scheme Advice for healthcare professionals to provide to patients: As these medicines carry risks of addiction, dependence and withdrawal reactions, before starting treatment with these medicines, your healthcare professional should explain how long you might need to take them for, and how to stop safely. This helps reduce the risk of addiction, dependence, and drug withdrawal syndrome. Anyone can become physically dependent on these medicines, meaning that their body gets used to it, and this can cause them to have withdrawal symptoms if the medicine is suddenly stopped, or the dose is reduced. Drug addiction can feel like a strong desire to take the medicine, and difficulties in controlling medicine use (for example feeling like you want to take more or use the medicine when you shouldn’t). Addiction and dependence are related but they are not the same, being physically dependent on a medicine does not necessarily mean you are addicted to it. Drug tolerance can mean no longer feeling like the medicine is working well, or feeling that a higher dose is required to achieve the same symptom relief as before. If you want to stop taking your medicine there are additional resources to help you. Never stop taking your medication without asking a healthcare professional first. If you are taking this medicine for epilepsy, you should keep taking it for as long as your doctor says it’s needed. If you find that your treatment is not working as well, you should speak to your healthcare professional about possible alternative treatment options, and you should never take more of your medicine than you have been prescribed. When it is time to stop your medication, your healthcare professional will tell you how to gradually reduce the amount of medicine you are taking over time (known as dose tapering). This is very important to reduce the risk of drug withdrawal syndrome. Dose tapering can sometimes take weeks or months. Mild symptoms may still occur, but you should contact your healthcare professional if the withdrawal symptoms become intolerable.- Posted
-
- Medication
- Adverse reaction
- (and 4 more)
-
Content Article
Medication adverse reactions and patient safety
Patient Safety Learning posted an article in Adverse interactions
Unsafe medication practices and medication-related harm are one of the leading causes of avoidable harm in health and care. This year’s #MedSafetyWeek focuses on the theme “we can all help make medicines safer”. We have collated patient interviews and blogs shared on the hub that raise awareness of medication adverse reactions, and resources on how you can report a problem. 1 MHRA: The Yellow Card Scheme The Yellow Card Scheme helps the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of all healthcare products in the UK to ensure they are acceptably safe for patients and those who use them. On the Yellow Card Scheme website you can report a suspected incident or problem. 2 The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Antidepressant medications are taken by millions of people globally. A small percentage of people who take them will experience rare but dangerous adverse reactions. In this interview, Katinka Blackford Newman tells us about her personal experience of antidepressant-induced psychosis and how this led her to campaign for increased awareness about side effects. She highlights a widespread lack of education and awareness about the risks associated with antidepressants and outlines why she is asking suicide prevention charities to ask callers one simple question about their medication. 3 Patient Safety Spotlight interview with Marie Lyon, chair of the Association for Children Damaged by Hormone Pregnancy Tests In this interview, Marie Lyon talks about her campaign for justice for families affected by hormone pregnancy tests, why she is passionate about reforming medicines regulation and the important role patient campaigners play in improving patient safety. 4 USA: FDA Adverse Event Reporting System (FAERS) public dashboard FAERS is the U.S. Food and Drug Administration (FDA) primary database for collecting and analysing adverse event reports, serious medication errors, and product quality complaints for prescription drugs and therapeutic biologics, containing reports submitted by healthcare professionals, consumers, and manufacturers. 5 Recognising adverse events and using the yellow card system Despite the role of the MHRA’s Yellow Card reporting system in pharmacovigilance in the UK, understanding and uptake of the scheme remains limited. East London NHS Foundation Trust share how they designed a survey to explore healthcare professionals’ awareness, usage and perceptions of the Yellow Card Scheme for reporting adverse drug reactions. 6 Post-SSRI Sexual Dysfunction: After 30 years, why is the health system still failing to recognise this life-limiting adverse effect? Post-SSRI Sexual Dysfunction (PSSD) is a long-term adverse effect of Selective Serotonin Reuptake Inhibitors (SSRIs), a type of antidepressant medication. In this opinion piece, Harriet Vogt, Patient Safety Partner at NHS Sussex Integrated Care Board, outlines the need for recognition and research into PSSD to allow patients to make truly informed choices when considering SSRIs. She looks at the impact PSSD has on the sexual and emotional lives of thousands of people and highlights a new research study analysing the obstacles to quantifying its incidence and prevalence. Harriet argues that while the health system is beginning to recognise the value of placing patients at the heart of efforts to improve safety, this focus on listening is rarely given to individual patients who express concern about the impact of their medication or treatment. 7 MHRA: Reporting a possible side effect to a medicine – a guide for Children and Young People The MHRA has produced a guide to download and share to help children and young people learn why it's important to report possible side effects of medication. 8 Sodium Valproate: The Fetal Valproate Syndrome Tragedy In this article, Sharon Hartles, member of the Open University’s Harm and Evidence Research Collaborative, reflects upon the use of Sodium Valporate, marketed as Epilim, to treat patients at risk of epilepsy and the subsequent harms in fetal development and birth defects that arose from its use. ‘ 9 Interview with Charlet Crichton, founder of UKCVFamily UKCVFamily was set up in November 2021 to support patients in the UK who have had an adverse reaction to a Covid-19 vaccination. The group provides help and advocacy as well as raising awareness amongst healthcare professionals, the media and the Government. In this video, founder of UKCVFamily Charlet Crichton talks to us about the side effects she experienced after having the AstraZeneca Covid vaccine. She outlines why she established the group and describes the support it offers to patients. She outlines some of the issues people face when trying to access diagnosis and treatment, and discusses the limitations of the MHRA's Yellow Card scheme in collecting data about adverse reactions. She also describes how healthcare professionals can support people with adverse reactions by taking their concerns seriously and investigating symptoms thoroughly. Share your stories Have you had an adverse reaction to medication? What do you think of the Yellow Card reporting system? Share your thoughts and experiences with us on the hub. You can comment below (you will need to be signed in first; sign up is free and easy) or email us at [email protected].- Posted
-
- Medication
- Side effects
- (and 5 more)
-
News Article
At aged 50, Susie Martin has already undergone her fair share of health procedures. She has endured dozens of surgeries - once going through five procedures in a single year - and will need to have screening for the rest of her life. She believes it’s all because of a drug her mother was given by medics during pregnancy. Ms Martin is one of the hundreds of victims of a “silent scandal” involving the pregnancy drug diethylstilbestrol - a synthetic form of the female hormone oestrogen, commonly known as DES, which has been linked to cancer. Like many others, she says the drug, also known as DES, caused her to develop a lifelong gynaecological condition. She now lives in fear for her health, facing tests each year to ensure she hasn’t developed cancer. A campaign group of more than 300 people, including Ms Martin and her mother Jennifer Bradley, is calling on the government to launch a public inquiry to address what it describes as a national scandal. Clare Fletcher, partner at the Broudie Jackson Canter solicitors, which represents the group, said: “This is the silent scandal, with victims suffering in pain for decades with limited medical support and no government recognition for what they have been through. “It is one of the most devastating pharmaceutical failures in UK history and the people whose lives have been marred by it deserve answers.” Read full story Source: The Independent, 4 November 2025- Posted
-
- Pregnancy
- Medication
-
(and 2 more)
Tagged with:
-
News Article
The Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to help keep medicines, medical devices, vaccines and blood products safe by reporting any side effects, device incidents and suspected fake medical products, as part of #MedSafetyWeek (3–9 November). The global campaign is marking its tenth year, bringing together more than 130 regulators and health organisations across 117 countries with one shared message: everyone has a role to play in medicine safety. Reporting matters more than ever With more people using medicines and medical devices than ever before – from weight loss treatments to wearable monitors – safety reporting is a key part of protecting public health. An estimated 2.5 million people in the UK are now using weight loss medicines, many bought online and delivered by post. Thousands use glucose sensors or blood-pressure monitors in the comfort of their own homes. As medicines and medical devices play a bigger role in daily life, including to prevent illness rather than treat it, public reporting of safety concerns is more important than ever. Professor Anthony Harnden, MHRA Chair, said: “Healthcare has changed significantly over the past decade, alongside advances in science and technology. Medicines and medical devices are part of everyday life for millions of people, and many are accessed in new ways, including online. “If you experience a side effect, notice a device isn’t working properly, or suspect a fake medical product, please tell us via the MHRA’s Yellow Card scheme. Your report could protect others – and it only takes minutes.” Read full story Source: MHRA, 3 November 2025- Posted
-
- Regulatory issue
- Medication
-
(and 2 more)
Tagged with:
-
Content Article
In this blog, Sling the Mesh discusses the powerful and thoughtful letter published in the journal Hernia by Nicholas T.H. Farr, titled “Absence of evidence is not evidence of absence – Rethinking NHS England’s inguinal hernia surgery decision aid.” Farr’s letter challenges a key statement in NHS England’s decision support tool (DST) for inguinal hernia surgery, which claims that “none” of the patients experienced allergic or autoimmune reactions to hernia mesh. Farr rightly points out that such a definitive claim is not supported by the available evidence – and more importantly, that it misrepresents the uncertainty that still exists in the scientific literature. “Saying there is no evidence of an event is not the same as stating the event did not occur.” This distinction is vital. It goes to the heart of informed consent and patient trust. Farr’s letter highlights that while manufacturers of mesh products often include warnings about potential allergic reactions in their Instructions for Use (IFUs), the DST fails to reflect this nuance. Instead, it presents a level of certainty that the evidence simply doesn’t justify. Further reading on the hub from Nicholas Farr Medical device safety: effective testing is key- Posted
-
- Medical device
- Womens health
- (and 7 more)
-
Content Article
This case example in the Pharmaceutical Journal explores how off-label drug holidays and other behavioural changes can be used to treat a patient with obsessive compulsive disorder taking sertraline who is experiencing sexual dysfunction. It demonstrates the importance of open communication, shared decision making and consistent follow up in finding ways to mitigate the impact of medication side effects on patients' lives. The article is free to access, but you will need to sign up for a free Pharmaceutical Journal account to view it.- Posted
-
- Medication
- Obsessive compulsive disorder
- (and 4 more)
-
Content Article
This French cohort study looked at the long-term prognosis of myocarditis after Covid-19 mRNA vaccination. It aimed to assess whether clinical outcomes and medical management differ from myocarditis following Covid infection and other origins. Using data from the French National Health Data System, all individuals aged 12 to 49 years hospitalised for myocarditis in France between December 27, 2020 and June 30, 2022 were included in the study. The authors found that people with post-vaccine myocarditis had less severe cardiovascular events than those with myocarditis of other origins at 18 months of follow-up. However, they stress that affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.- Posted
-
- Vaccination
- Side effects
-
(and 3 more)
Tagged with:
-
Content Article
Chronic non-cancer pain (CNCP) is one of the most common causes of disability globally. Opioid prescribing to treat CNCP remains widespread, despite limited evidence of long-term clinical benefit and evidence of harm such as problematic pharmaceutical opioid use (POU) and overdose. This study aimed to measure the prevalence of POU in CNCP patients treated with opioid analgesics. Problematic pharmaceutical opioid use appears to be common in chronic pain patients treated with opioid analgesics, with nearly one in 10 experiencing dependence and opioid use disorder, one in three showing signs and symptoms of dependence and opioid use disorder and one in five showing aberrant behaviour.- Posted
-
- Medication
- Pain
-
(and 3 more)
Tagged with:
-
Content Article
Despite not being indicated for lactation in the UK, the anti-sickness medicine domperidone is increasingly being prescribed or bought illegally to aid lactation, but its side-effects can include anxiety, depression and suicidal thoughts. In this account for The Guardian, Rose Stokes describes her experience of being prescribed domperidone after the birth of her son. When her milk production didn't increase and with her mental health rapidly deteriorating, Rose bought her own supply of the drug online and through a private doctor and ended up taking more than five times the NHS maximum dose. When her mental state continued to worsen, she decided to suddenly stop taking domperidone which left her suicidal. She describes receiving no guidance on the mental health risks associated with the medication or sudden withdrawal.- Posted
-
- Medication
- Maternity
-
(and 3 more)
Tagged with:
-
News Article
Data on weight loss jab link to suicidal thoughts needs ‘urgent clarification’
Patient Safety Learning posted a news article in News
Data that suggests a weight loss jab may be linked to people having suicidal thoughts needs urgent clarification, experts have said. According to a new study, figures from a World Health Organization (WHO) database suggest a bigger proportion of reports about the drug semaglutide (Wegovy) mentioned suicidal thoughts. This is when compared to liraglutide (another weight loss drug, also known as Saxenda). This study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification This was particularly the case among patients who also reported taking antidepressants, the study found. The researchers of the study, published in Jama Network Open, say the findings warrant “urgent clarification”. Read full story Source: The Independent, 20 August 2024- Posted
-
- Obesity
- Medication
-
(and 2 more)
Tagged with:
-
News Article
Opioid painkillers put millions at risk of addiction or dependency
Patient Safety Learning posted a news article in News
Millions of people are addicted to, or at risk of becoming dependent on, prescription opioid painkillers, according to international research. The study found that one in three people taking prescribed opioid analgesics, which include codeine, tramadol, oxycodone and morphine, show symptoms of being dependent on them, while one in 10 become fully dependent on the drugs. The research, led by academics from the University of Bristol and published in the journal Addiction, also showed that one in eight people are at risk of prescription opioid misuse. It examined data from 148 international studies involving more than 4.3 million patients aged 12 and over who had non-cancer pain for three months or longer and who were prescribed the medicines. While they are useful for short-term acute pain and managing end-of-life care, “opioid painkillers are not effective in the management of long-term pain,” said Kyla Thomas, a professor of public health medicine at the University of Bristol and lead author of the study. “They are associated with many harms. Our findings show that opioid misuse is much more common among patients taking them for long-term pain than perhaps people imagine.” Read full story Source: The Guardian, 7 August 2024- Posted
-
- Pain
- Side effects
-
(and 2 more)
Tagged with:
-
News Article
Almost half of antidepressant users could quit with GP support, study finds
Patient Safety Learning posted a news article in News
Almost half of long-term antidepressant users could stop taking the medication with GP support and access to internet or telephone helplines, a study suggests. Scientists said more than 40% of people involved in the research who were well and not at risk of relapse managed to come off the drugs with advice from their doctors. They also discovered that patients who could access online support and psychologists by phone had lower rates of depression, fewer withdrawal symptoms and reported better mental wellbeing. Prof Tony Kendrick, of Southampton University, who was the lead author of the research, said the findings were significant because they showed high numbers of patients withdrawing from the drugs without the need for costly intense therapy sessions. He said: “This approach could eliminate the risk of serious side-effects for patients using antidepressants for long periods who have concerns about withdrawal. “Offering patients internet and psychologist telephone support is also cost-effective for the NHS. Our findings show that support not only improves patient outcomes but also tends to reduce the burden on primary healthcare while people taper off antidepressants.” Read full story Source: The Guardian, 26 June 2024- Posted
-
- Medication
- Mental health
-
(and 5 more)
Tagged with:
-
News Article
Antidepressant withdrawal affects one in six people
Patient Safety Learning posted a news article in News
One out of every six people have symptoms when they stop taking antidepressants - fewer than previously thought, a review of previous studies suggests. The researchers say their findings will help inform doctors and patients "without causing undue alarm". The Lancet Psychiatry review looked at data from 79 trials involving more than 20,000 patients. Some had been treated with antidepressants and others with a dummy drug or placebo, which helped researchers gauge the true effect of withdrawing from the drugs. Some people have unpleasant symptoms such as dizziness, headache, nausea and insomnia when they stop taking antidepressants, which, the researchers say, can cause considerable distress. Previous estimates suggested antidepressant discontinuation symptoms (ADS) affected 56% of patients, with almost half of cases classed as severe. But this review, from the Universities of Berlin and Cologne, estimates one out of every every six or seven patients can expect symptoms when stopping antidepressants and one in 35 will have severe symptoms. Read full story Source: BBC News, 6 June 2024- Posted
-
- Medication
- Side effects
-
(and 2 more)
Tagged with:
-
News Article
Man says he has been 'left to rot' after Covid vaccine
Patient Safety Learning posted a news article in News
On 15 December 2021 Larry Lowe’s life changed. He was 54, rarely ill, fit, healthy and running 10km most days – until he got the Pfizer Covid booster. Within days he developed numbness in the right side of his face and started experiencing pain. "I had lost all the feeling in my face, teeth, nose, tongue, eye, that whole side of my head," he said. These symptoms have spread through his body and intensified over the years, with doctors across the UK saying the vaccine is to blame. Pfizer said patient safety was paramount and it took reports of adverse reactions very seriously. It said hundreds of millions of doses had been administered globally "and the benefit-risk profile of the vaccine remains positive for all authorised indications and age groups". Mr Lowe said that while he was not opposed to vaccines, his life had been destroyed. Read full story Source: BBC News, 14 October 2024 Related reading on the hub: Interview with Charlet Crichton, founder of UKCVFamily Adverse reactions to Covid-19 vaccination - are adverse reactions adequately understood and are patients affected provided for in your area?- Posted
-
- Vaccination
- Virus
-
(and 2 more)
Tagged with:
-
News Article
Families failed by Covid jabs tell inquiry of pain
Patient-Safety-Learning posted a news article in News
Families of those harmed by Covid vaccines told the UK Covid Inquiry they were forced to support each other during the pandemic because there was no other help. Kate Scott, who represents the group Vaccine Injured and Bereaved UK (VIBUK), said they felt they were "almost being pushed into the shadows during the pandemic." The inquiry also heard from a victims' group in Scotland which raised concerns that the vaccine had been rolled out too quickly, and that safety had been sacrificed for speed. This is the Inquiry's fourth module, which will consider issues relating to the development of Covid-19 vaccines and their implementation. Mrs Scott, whose husband Jamie was left severely disabled by a vaccine, said, "We are an uncomfortable truth, but we are a truth and the truth is for everyone in our group—the vaccine caused serious harm and death." Jamie Scott, a father of two boys, worked in a high-powered job until he was severely injured by a Covid vaccine. He spent four weeks and five days in a coma and suffered an extremely rare, life-threatening side effect called VITT, or vaccine-induced immune thrombosis and thrombocytopenia. Jamie survived, but suffered a significant brain injury, which affected his thinking processes. He is now partially blind and his wife says he will never live independently. Jamie has received £120,000 - the maximum payout from the government's Vaccine Damage Payment Scheme. His wife, who is clear that neither of them is against vaccines, says he will never work again and that this is not a fair or adequate amount. Read full story Watch an interview on the hub with Charlet Crichton, founder of UKCVFamily, a support group for patients in the UK who have had an adverse reaction to a Covid-19 vaccination. Source: BBC News, 15 January 2025- Posted
-
- Vaccination
- Patient death
-
(and 3 more)
Tagged with:
-
Content Article
Antidepressant medications are taken by millions of people globally. A small percentage of people who take them will experience rare but dangerous adverse reactions. In this interview, Katinka Blackford Newman tells us about her personal experience of antidepressant-induced psychosis and how this led her to campaign for increased awareness about side effects. She highlights a widespread lack of education and awareness about the risks associated with antidepressants and outlines why she is asking suicide prevention charities to ask callers one simple question about their medication.- Posted
- 1 comment
-
2
-
- Medication
- Prescribing
- (and 5 more)
-
Content Article
Over 65% of all new drugs undergo expedited drug approval in the USA, and these drugs have been linked to a higher prevalence of adverse drug reactions, raising concerns about safety. It is well documented that women generally report a higher frequency of adverse drug reactions than men, but whether women have more adverse drug reactions than men from drugs approved via expedited pathways is unknown. This brief Lancet article outlines the findings of a systematic review that assessed sex differences in data reporting and highlighted a knowledge gap as to whether women face a higher risk of harm through expedited approval pathways than men.- Posted
-
- Womens health
- Clinical trial
- (and 4 more)
-
News Article
The side effects of different antidepressants have been ranked - revealing a huge difference between drugs. Researchers looked at the impact medications had on patients in the first eight weeks of starting treatment. It revealed individuals prescribed certain antidepressants may gain up to 2kg in weight, vary heart rate by as much as 21 beats every minute or have changes in blood pressure. “Antidepressants are among the most widely used medicines in the world. While many people benefit from them, these drugs are not identical – some can lead to meaningful changes in weight, heart rate, and blood pressure in a relatively short period,” said senior author of the study Dr Toby Pillinger, an academic clinical lecturer at King’s IoPPN, a consultant psychiatrist. Led by experts from King’s College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN), the team analysed data from 58,534 participants across over 150 studies, comparing 30 antidepressants against a dummy drug, known as a placebo. Researchers said that the findings, which have been published in The Lancet, should “empower” patients but urged them to speak with a medic if they have any concerns. Study author Andrea Cipriani, professor of psychiatry at the University of Oxford, added: “Most clinical decisions – especially in mental health – are still made by physicians with little input from patients. “Our results emphasise the importance of shared decision making, the collaborative process through which patients are supported by the clinicians to reach a decision about their treatment, bringing together their preferences, personal circumstances, goals, values and beliefs. “This should be the way forward in the NHS and globally.” Read full story Source: The Independent, 22 October 2025 Related reading on the hub: Antidepressant Risks - Adverse interactions The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Post-SSRI Sexual Dysfunction: After 30 years, why is the health system still failing to recognise this life-limiting adverse effect? Long-lasting sexual dysfunction after taking antidepressants: Lack of recognition harmful to patients- Posted
-
- Medication
- Depression
-
(and 3 more)
Tagged with:
-
Content Article
Recently, The Conversation ran an article which claimed to “debunk” a range of myths about antidepressants such as selective serotonin reuptake inhibitors (SSRIs). Natalina Salmaso, a clinical psychologist at Carleton University in Canada, highlighted five common myths that make people hesitant to take antidepressants. In this article, Maryanne Demasi and Peter C Gøtzsche argue that The Conversation article was full of omissions and falsehoods and want to debunk the debunker. Related reading on the hub: The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Long-lasting sexual dysfunction after taking antidepressants: Lack of recognition harmful to patients- Posted
-
- Medication
- Prescribing
-
(and 4 more)
Tagged with:
-
Content Article
Film: "Medicating Normal" (19 April 2024)
Patient Safety Learning posted an article in Medication
This full-length, award-winning documentary unearths the shattering truth that millions of people worldwide are injured by prescribed psychiatric medications. Interweaving stories of harm with expert testimony, the film reveals how a profit-driven industry hides the risks of long-term use. This untold story is a compelling call to examine the consequences of medicating normal human suffering.- Posted
-
- Medication
- Mental health
- (and 5 more)